EMA Authorised: Siiltibcy (Mycobacterium tuberculosis derived antigens (rdESAT‑6 and rCFP‑10)) — Serum Life Science Europe GmbH

View source ↗

Summary

EMA has authorised Siiltibcy, a tuberculosis diagnostic product using M. tuberculosis–derived antigens rdESAT-6 and rCFP-10, developed by Serum Life Science Eur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Siiltibcy

Snippet

Status: Authorised. Therapeutic area: Tuberculosis;Diagnosis. MAH: Serum Life Science Europe GmbH. Decision date: 24/10/2025